Nitrosamine Standards have been launched by the Indian Pharmacopoeia Commission (IPC) to strengthen the testing and quality control of medicines in India. On 25 August 2026, the IPC introduced seven Indian Pharmacopoeia Nitrosamine Impurities Reference Standards during its first interactive meeting held at the Central Drugs Laboratory and Central Cosmetics Laboratory in Kolkata, West Bengal.

The new standards are expected to help laboratories identify and measure very small amounts of nitrosamine impurities in pharmaceutical products. The move is important for medicine safety because some nitrosamines are associated with genotoxic and carcinogenic effects.

Indian Pharmacopoeia Commission and Drug Quality

The Indian Pharmacopoeia Commission is an autonomous organisation working under the Ministry of Health and Family Welfare. It develops official standards for medicines used in India and supports quality control through pharmacopoeial standards and reference materials.

The Indian Pharmacopoeia provides specifications that help determine the identity, purity, strength and quality of medicines. These standards are used by pharmaceutical manufacturers, testing laboratories and regulatory authorities.

The latest initiative expands the reference materials available for monitoring nitrosamine impurities and supports more consistent laboratory testing.

What Are Nitrosamine Impurities?

Nitrosamines are a group of chemical compounds that can occur unintentionally during the production or storage of medicines. They may form because of chemical reactions involving certain ingredients, manufacturing processes or storage conditions.

Some nitrosamines have been identified as potentially harmful because of their genotoxic and carcinogenic properties. Genotoxic substances can damage genetic material, while carcinogenic substances may increase the risk of cancer under certain conditions and levels of exposure.

For this reason, pharmaceutical regulators around the world have increased their focus on detecting and controlling nitrosamine impurities.

Seven Nitrosamine Reference Standards

The IPC has introduced seven specific reference standards:

N-Nitrosodimethylamine (NDMA)
N-Nitrosodiethylamine (NDEA)
N-Nitrosoethylisopropylamine (NEIPA)
N-Nitrosodibutylamine (NDBA)
N-Nitrosomethylphenylamine (NMPA)
N-Nitrosodiisopropylamine (NDIPA)
N-Nitroso-N-methyl-4-aminobutyric acid (NMBA)

These substances can now be compared against officially prepared reference materials during laboratory analysis.

How Reference Standards Help Laboratories

Reference standards are important tools in pharmaceutical testing. A laboratory can use a known reference substance to identify whether the same impurity is present in a medicine sample.

The standards can also help laboratories determine the amount of an impurity present in a particular sample. This makes testing more accurate and allows manufacturers and regulators to compare results using common benchmarks.

The availability of domestic reference standards can also support pharmaceutical quality testing within India and reduce dependence on external sources for certain analytical materials.

Importance for Long-Term Medicines

The control of nitrosamine impurities is particularly relevant because medicines for long-term health conditions may be taken by patients for extended periods.

Nitrosamine monitoring has received attention in medicines used for conditions including high blood pressure, gastric disorders, diabetes and tuberculosis. Maintaining strict quality standards is therefore important throughout the manufacturing and supply chain.

The presence of an impurity does not automatically mean that a medicine is unsafe. Its risk depends on factors such as the specific substance, quantity, exposure and duration. Regulatory testing is used to identify and control such impurities.

IPC Meeting in Kolkata

The launch took place during the IPC’s first interactive meeting at the Central Drugs Laboratory and Central Cosmetics Laboratory in Kolkata.

The meeting was held under the theme “IP 2026: Perspectives, Suggestions & Way Forward.” Industry representatives, experts and other stakeholders participated in discussions on pharmaceutical standards and quality-related issues.

Such interactions provide an opportunity for regulators, laboratories and the pharmaceutical industry to discuss emerging challenges and improve testing practices.

Strengthening Pharmaceutical Quality in India

The launch of the Nitrosamine Standards comes at a time when pharmaceutical quality and supply-chain safety are receiving greater attention globally. Modern medicines often involve complex manufacturing processes, making reliable impurity testing an important part of quality assurance.

India has a large pharmaceutical manufacturing sector and supplies medicines to many countries. Strong domestic testing capabilities can therefore support both the Indian market and the country’s wider pharmaceutical industry.

The new reference standards can help testing laboratories establish more reliable methods for detecting nitrosamine impurities and support manufacturers in monitoring their products.

Role of Pharmacopoeial Standards

Pharmacopoeial standards provide a common technical basis for checking medicines. They define important characteristics such as the identity, purity, strength and quality of pharmaceutical substances and products.

By adding seven nitrosamine impurity reference standards, the IPC is strengthening the tools available for impurity profiling and analytical quality control.